CHARMOT DOMINIQUE,JACOBS JEFFREY W,LEADBETTER MICHAEL ROBERT,NAVRE MARC,CARRERAS CHRIS,BELL NOAH
申请号：
IN5002/CHENP/2011
公开号：
IN2011CN05002A
申请日:
2011.07.12
申请国别(地区):
IN
年份:
2012
代理人:
摘要：
The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound,......
